Guidelines Platform Update Liisa Pylkkanen Healthcare Quality Team Joint Research Centre the European Commission's in-house science service JRC Science Hub: ec.europa.eu/jrc
The Guidelines Platform will cover all BC care processes 2 DGD and QASDG Meetings - 15. 16.3.2016 Varese
Guidelines Platform - WEB-BASED PLATFORM for all stakeholders The Guidelines Platform will be a web-based platform, with efficient search tools for identifying guidelines and recommendations for different breast cancer processes. In development the patient-centred approach will be the key element. All information and recommendations provided in the Guidelines Platform will be presented in a user-friendly manner and by using clear language, understandable to all potential users. The Guidelines Platform will also be regularly updated to include new guidelines and recommendations. 3 DGD and QASDG Meetings - 15. 16.3.2016 Varese
Eligibility criteria (search performed by Iberoamerican Cochrane) Study design 1. Documents containing at least one breast cancer services recommendation irrespectively of its stage (prevention, screening, diagnosis, treatment, rehabilitation, follow up, support to long term survivors, palliative and end of life care). 2. Documents including recommendations based on a systematic review [to be assessed in the full text of documents initially screened from the search]. a. By systematic review we will consider documents that include an explicit strategy to search for the evidence and an assessment of the risk of bias of the evidence of the included studies. 3. Documents published in the period 2006 2015. Population 1. Women or men Category and practices considered 1. Prevention 2. Surveillance 3. Screening 4. Diagnosis 5. Treatment (by any professional specialty / type of treatment / stage of disease) 6. Rehabilitation (by any professional specialty / type of approach) 7. Follow-up 8. Support to long term survivors (by any professional specialty/type of approach) 9. Palliative care 10. End of life care (by any professional specialty/type of approach) 4 DGD and QASDG Meetings - 15. 16.3.2016 Varese
Sources consulted and strategy designed to conduct the search SOURCES GUIDELINES DATABASES 1. GIN s International Guidelines Library (www.g-i-n.net/library/internationalguidelines-library). 2. AHRQ s Guidelines Clearinghouse (www.guideline.gov/). 3. NICE s Evidence Search (www.evidence.nhs.uk/; search restricted to Guidance in Types of information ). 4. Canadian Medical Association Infobase (www.cma.ca/en/pages/clinicalpractice-guidelines.aspx) 5. Australian NHMRC Clinical Practice Guidelines portal (www.clinicalguidelines.gov.au/) 6. U.S. Preventive Services Task Force recommendations (www.uspreventiveservicestaskforce.org/page/name/recommendations) BIBLIOGRAPHIC DATABASES 1. PubMed (www.ncbi.nlm.nih.gov/pubmed) 2. EMBASE (accessed via Ovid) 3. CINAHL (accessed via EBSCOhost). STAKEHOLDER S WEBSITES Listed at Appendix 1 SEARCH STRATEGY TERMS We searched all the mentioned sources with the following terms or combinations of terms 1. breast cancer 2. screening AND breast 3. mammography We used controlled vocabulary in the sources allowing implementing this feature. We report at the results section the search algorithms designed to each database and the hits retrieved. LIMITS and FILTERS We considered for inclusion documents published in the period 2006 2015. We did not set language limits to the searches. We established in the bibliographic databases (i.e. PubMed and CINHAL) study design filters adapted from the search filter used by NICE for identifying guidelines: 5 DGD and QASDG Meetings - 15. 16.3.2016 Varese
PRISMA FLOW CHART GUIDELINES REPOSITORIES GIN s International Guidelines Library 127 AHRQ s Guidelines Clearinghouse 435 NICE guidance 25 Canadian Medical Association Infobase 36 Australian NHMRC Guidelines portal 9 BIBLIOGRAPHIC DATABASES MEDLINE 664 EMBASE 913 CINAHL 280 SOCIETIES WEBSITES ASCO 14 DGHO 2 ACS 2 NIH NCI 4 ESMO 3 NBCG 1 ASBS 7 SIIM 1 ASPS 1 SNMMI 3 CAP 1 SweBCG 1 EANM 1 USPSTF 19 EFSUMB 1 WCRF 1 1545 records screened after elimination of duplicates 1238 from databases 245 from guidelines repositories 62 from websites 1313 records excluded by title/abstract 232 documents included 6 DGD and QASDG Meetings - 15. 16.3.2016 Varese
Guidelines Platform TASKS and TIMELINES for 2015-2017 HOW is the Guidelines Platform developed and maintained? Systematic search on evidence-based guidelines has been performed (results obtained by 11.03.2016 and under review at the JRC) Call for guidelines concerning all processes of breast cancer (planned for Q1-Q2/2016) Evaluation of the quality of BC guidelines by the AGREE II tool (in Q2-Q3/2016 tendering process ongoing, to be launched in 04/2016) Web-site ready by Q4/2016 Continuous updating process to be defined and reported in Q4/2016 Launch of the Guidelines Platform is planned in Q1/2017 7 DGD and QASDG Meetings - 15. 16.3.2016 Varese
EXTRA SLIDES 8 DGD and QASDG Meetings - 15. 16.3.2016 Varese
Guidelines Platform SCOPE Type of recommendations (adapted from DECIDE) Recommendations about preventive, therapeutic, or rehabilitative interventions; Recommendations about tests used for diagnostic, screening, monitoring or other purposes; Decisions made on behalf of a population about which clinical interventions are paid for by a third party (i.e., coverage decisions); and Recommendations and decisions made on behalf of a population about health system and public health interventions. 9 DGD and QASDG Meetings - 15. 16.3.2016 Varese
Guidelines Platform - CONCLUSIONS The Guidelines Platform can be foreseen as a valuable resource of guidelines for professionals, policymakers, researchers, guidelines developers, as well as for citizens and patients. The platform will provide evidence for the European QA scheme; on the other hand implementation of guidelines is guaranteed through certification according to European QA scheme. The ultimate impact of the Guidelines Platform would be to reduce unnecessary variability in healthcare services and hence improve the outcomes of breast cancer patients in terms of morbidity, mortality, and the quality of life. Support also for this ECIBC project is highly appreciated! 10 DGD and QASDG Meetings - 15. 16.3.2016 Varese